QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 stitch-fix-posts-q4-results-joins-transocean-mbx-biosciences-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Stitch Fix, Inc....

 hc-wainwright--co-reiterates-buy-on-galectin-therapeutics-maintains-6-price-target

HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $6 pr...

 galectin-therapeutics-q2-eps-012-beats-016-estimate

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of...

 hc-wainwright--co-assumes-galectin-therapeutics-at-buy-announces-price-target-of-6

HC Wainwright & Co. analyst Joseph Pantginis assumes Galectin Therapeutics (NASDAQ:GALT) with a Buy rating and announces...

 galectin-therapeutics-q1-eps-015-beats-020-estimate

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of...

 galectin-therapeutics-issues-presentation-highlighting-its-focused-pipeline-mash-cirrhosis-and-oncology-developing-galectin-based-therapeutics-to-improve-the-lives-of-patients-with-chronic-liver-diseases-and-cancer

https://docs.publicnow.com/viewDoc?hash_primary=6F7EA1F91A74272903B9A6CE2CA3BF2D89B3FA18

 hc-wainwright--co-reiterates-neutral-on-galectin-therapeuticsto-neutral

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) from Neutral to Neutral.

 hc-wainwright--co-downgrades-galectin-therapeutics-to-neutral

HC Wainwright & Co. analyst Ed Arce downgrades Galectin Therapeutics (NASDAQ:GALT) from Buy to Neutral.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION